medRxiv

[키워드] Admission Anakinra analysed Antiviral antivirals article articles Baricitinib case reports Characteristics Chloroquine Clinical features clinical impact Colchicine combination therapy control group COVID-19 COVID-19 patient cumulative Cytokine release syndrome database deaths Dexamethasone discharge disease dysregulation Efficacy eligibility criteria English language Evidence exclusion explain Favipiravir first stage Google Scholar helping High-flow oxygen Hydroxychloroquine identify immune immune dysregulation immune response Inclusion Inconclusive indicated Infection intensive care intensive care unit intensive care unit admission item itolizumab large trial Loading dose Lopinavir Lopinavir/ritonavir management medRxiv meta-analyses Mortality Open-label oxygen Pathogenesis pathogenesis of COVID-19 pathogenic mechanism patients primary end point PRISMA Randomised controlled trials rationale RCTs reduced reduction Remdesivir removal reported Reporting requiring high-flow oxygen retrospective review Ritonavir ruxolitinib sarilumab SARS-CoV-2 SARS-COV-2 infection significantly siltuximab supportive therapy systematic review systematic reviews the disease the SARS-CoV-2 therapeutic therapeutic agent Therapeutic approach therapeutic approaches therapy Time to recovery Tocilizumab Treatment treatment of COVID-19 patients Trial trials triggered USA was performed were excluded
[DOI] 10.1007/s40265-020-01421-w PMC 바로가기 [Article Type] Article